申请人:Taltavull Moll Joan
公开号:US20080221096A1
公开(公告)日:2008-09-11
The present disclosure relates to a pyridofuropyrimidine derivative of formula (I):
wherein
G
1
is a group chosen from —CR
6
R
7
— and —O— wherein R
6
and R
7
are independently chosen from hydrogen atoms and C
1-4
alkyl groups; R
1
and R
2
are independently chosen from hydrogen atoms and C
1-4
alkyl groups; R
3
is chosen from C
1-4
alkyl, C
1-4
alkoxy, amino, hydroxy, mono-C
1-4
alkylamino, di-C
1-4
alkylamino, C
3-8
cycloalkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups which are bound to the pyridine ring through their nitrogen atom, all of them being optionally substituted by one or more substituents chosen from halogen atoms and hydroxy, C
1-4
alkyl, C
1-4
alkoxy-C
1-4
alkyl, aryl-C
1-4
alkyl, —O(CO)OR
8
, C
1-4
alkoxy, —(CO)NR
8
R
9
, —CN, —CF
3
, —NR
8
R
9
, —SR
8
and —SO
2
NH
2
groups wherein R
8
and R
9
are each independently chosen from a hydrogen atom or a C
1-4
alkyl group; R
4
and R
5
are independently chosen from hydrogen atoms, C
1-4
alkyl groups, hydroxyl-C
1-4
alkyl groups and groups of formula (II):
wherein p and q are integers chosen from 0, 1, 2 and 3; A is either a direct bond or a group chosen from —CONR
14
—, —NR
14
CO—, —O—, —COO—, —OCO—, —S—, —SO— and —SO
2
—, wherein each R
10
, R
11
, R
12
, R
13
and R
14
are independently chosen from a hydrogen atom and a C
1-4
alkyl group and G
2
is chosen from aryl, heteroaryl and heterocyclyl groups; wherein the group G
2
is optionally substituted by one or more substituents chosen from halogen atoms and C
1-4
alkyl, hydroxy, oxo, C
1-4
alkoxy-C
1-4
alkyl, aryl-C
1-4
alkyl, —(CO)OR
16
, C
1-4
alkoxy, —(CO)NR
16
R
17
, —CN, —CF
3
, —NR
16
R
17
—SR
16
and —SO
2
NH
2
groups; wherein R
16
and R
17
each independently chosen from hydrogen atom and a C
1-4
alkyl group and the pharmaceutically acceptable salts and N-oxides thereof.
本公开涉及一种式为(I)的吡啶并呋喃嘧啶衍生物:
其中G1是从—CR6R7—和—O—中选择的基团,其中R6和R7分别选择自氢原子和C1-4烷基基团;R1和R2分别选择自氢原子和C1-4烷基基团;R3选择自C1-4烷基、C1-4烷氧基、氨基、羟基、单C1-4烷基氨基、双C1-4烷基氨基、C3-8环烷基氨基、芳基、杂芳基和饱和N-含杂环基团,它们通过它们的氮原子与吡啶环相连,所有这些基团都可以被一个或多个取代基取代,所述取代基选择自卤素原子和羟基、C1-4烷基、C1-4烷氧基-C1-4烷基、芳基-C1-4烷基、—O(CO)OR8、C1-4烷氧基、—(CO)NR8R9、—CN、—CF3、—NR8R9、—SR8和—SO2NH2基团,其中R8和R9各自选择自氢原子或C1-4烷基基团;R4和R5分别选择自氢原子、C1-4烷基基团、羟基-C1-4烷基基团和式(I)的基团:
其中p和q是选择自0、1、2和3的整数;A是直接键或从—CONR14—、—NR14CO—、—O—、—COO—、—OCO—、—S—、—SO—和—SO2—中选择的基团,其中每个R10、R11、R12、R13和R14各自选择自氢原子和C1-4烷基基团,G2选择自芳基、杂芳基和含杂环基团;其中基团G2可以被选择自卤素原子和C1-4烷基、羟基、氧代、C1-4烷氧基-C1-4烷基、芳基-C1-4烷基、—(CO)OR16、C1-4烷氧基、—(CO)NR16R17、—CN、—CF3、—NR16R17—SR16和—SO2NH2基团的一个或多个取代基取代;其中R16和R17各自选择自氢原子和C1-4烷基基团,以及其药学上可接受的盐和N-氧化物。